Fakultna Nemocnica Nitra

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis5 trials
• Macular degeneration4 trials
• Chronic kidney disease2 trials
• Primary biliary cholangitis2 trials
• Stroke2 trials
• Atrial fibrillation1 trial
• Coeliac disease1 trial
• Coronary artery disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Liver cirrhosis1 trial
• and 5 more

Phase

• Phase 316 trials
• Phase 24 trials

Status

• Active, not recruiting9 trials
• Completed7 trials
• Recruiting3 trials
• Not yet recruiting1 trial

Lead sponsor

• Pfizer3 trials
• AstraZeneca2 trials
• Bayer2 trials
• Novartis Pharma AG2 trials
• Novartis Pharmaceuticals2 trials
• and 9 more

Running trials

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Amgen· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

  NCT07216235· Phase 3· Zydus Therapeutics Inc.· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

  2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source

• Active, not recruiting

  A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

  NCT06557772· Phase 2· Sanofi· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· AstraZeneca· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Phase 3· Pfizer· Source

• Active, not recruiting

  An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS

  2023-507906-15-00· Phase 3· Novartis Pharma AG· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Primary biliary cholangitis2 recruiting
• Macular degeneration1 recruiting
• Multiple sclerosis1 recruiting

Closed trials

• Completed

  A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

  NCT06269484· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Pfizer· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT04740671· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Bayer· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source